Trials / Unknown
UnknownNCT01869309
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- LifeBridge Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet reactivity defined as Vasodilator Stimulated Phosphoprotein-Phosphorylation (VASP-P) \>50%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasugrel | Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily. |
| DRUG | Ticagrelor | Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily). |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-12-01
- Completion
- 2016-12-01
- First posted
- 2013-06-05
- Last updated
- 2014-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01869309. Inclusion in this directory is not an endorsement.